CPRX - CATALYST PHARMACEUTICALS, INC.

QQQ $ 439.30 $ -1.16 (-0.26 %)

DIA $ 391.20 $ 1.09 (0.28 %)

SPY $ 517.41 $ -0.03 (-0.01 %)

TLT $ 89.90 $ -0.14 (-0.16 %)

GLD $ 214.87 $ 0.17 (0.08 %)

Previous Close

$ 14.72

Open

$ 14.92

Bid

$ 15.11 x 200

Ask

$ 15.25 x 100

Day's Range

$ 14.54 - $ 15.28

52 Week Range

$ 11.09 - $ 17.74

Volume

1,099,681

Average Volume

Market Cap

1.82B

Beta (5Y Monthly)

$ 1.16

PE Ratio (TTM)

$ 27.90

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-28-2024	12-31-2023	10-K
3	11-08-2023	09-30-2023	10-Q
4	08-09-2023	06-30-2023	10-Q
5	05-10-2023	03-31-2023	10-Q
6	03-15-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-16-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-15-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-11-2020	03-31-2020	10-Q
18	03-16-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-10-2019	03-31-2019	10-Q
22	03-18-2019	12-31-2018	10-K
23	11-07-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	03-14-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-09-2017	06-30-2017	10-Q
29	05-10-2017	03-31-2017	10-Q
30	03-15-2017	12-31-2016	10-K
31	11-09-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-10-2016	03-31-2016	10-Q
34	03-15-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	08-10-2015	06-30-2015	10-Q
37	05-11-2015	03-31-2015	10-Q
38	03-13-2015	12-31-2014	10-K
39	11-13-2014	09-30-2014	10-Q
40	08-13-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Catalyst Pharmaceuticals Reaffirms FY24 To...
05/08/2024 20:49:02

Reaffirm the 2024 full-year total revenue guidance in the range of $455 million and $475 million.

Catalyst Pharmaceuticals Q1 Adj $0.38 Beat...
05/08/2024 20:22:33

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate...

Decoding 7 Analyst Evaluations For Catalys...
03/27/2024 13:00:53

Oppenheimer Reiterates Outperform on Catal...
03/27/2024 11:32:44

Oppenheimer analyst Leland Gershell reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Outperform and maintains $29 pr...

Cantor Fitzgerald Reiterates Overweight on...
03/22/2024 18:00:39

Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $...

Cantor Fitzgerald Reiterates Overweight on...
03/14/2024 14:19:31

Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $...

Citigroup Initiates Coverage On Catalyst P...
03/14/2024 12:02:26

Citigroup analyst Samantha Semenkow initiates coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy rating and annou...

Catalyst Pharmaceuticals Announces AGAMREE...
03/13/2024 12:01:38

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolera...

Assessing Catalyst Pharmaceuticals: Insigh...
03/07/2024 17:00:55

B of A Securities Initiates Coverage On Ca...
03/07/2024 16:00:44

B of A Securities analyst Jason Gerberry initiates coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy rating and ...

Cantor Fitzgerald Maintains Overweight on ...
03/01/2024 14:54:32

Cantor Fitzgerald analyst Charles Duncan maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and raises the p...

HC Wainwright & Co. Reiterates Buy on Cata...
03/01/2024 11:37:11

HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $24 p...

top-3-health-care-stocks-you-may-want-to-dump-in-q1

Top 3 Health Care Stocks You May Want To D...
02/29/2024 15:40:19

As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as...

Catalyst Pharmaceuticals Expects 2024 Tota...
02/29/2024 07:31:23

Catalyst Pharmaceuticals Q4 Adj. EPS $0.53...
02/29/2024 07:29:37

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly adjsuted earnings of $0.53 per share which beat the analyst consensus...

Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

Earnings Preview For Catalyst Pharmaceuticals
02/27/2024 18:01:59

Catalyst Pharmaceuticals To Present At MDA...
02/27/2024 13:17:31

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical compan...

Catalyst Pharmaceuticals Announces Publica...
02/21/2024 14:03:31

jim-cramer-likes-this-bank-very-very-much-says-stock-is-up-7-over-past-6-months

Jim Cramer Likes This Bank 'Very, Very Muc...
01/22/2024 13:43:19

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc.